Harmony Biosciences schedules Phase 3 HBS-301 trial data presentations
HRMY•Harmony Biosciences scheduled a poster presentation on Phase 3 trials of investigational HBS-301 at European Narcolepsy Days in Bern for Oct. 2 and 3, 2026; results have not yet been presented.
1. Poster presentation scheduled
The poster will cover Phase 3 trials of HBS-301, a high-dose, optimized enteric-coated pitolisant tablet formulation being developed for excessive daytime sleepiness in narcolepsy. The program also targets idiopathic hypersomnia, with adult Phase 3 studies underway in ONSTRIDE-1 and ONSTRIDE-2.
